Omeros (OMER) said Wednesday the results of a study evaluating the efficacy and safety of its investigational drug narsoplimab to treat hematopoietic stem...
Omeros (OMER) reported a Q4 adjusted net loss of $0.37 per share late Tuesday, compared with a loss of $0.36 per share in Q3. The biopharmaceutical...
Omeros (OMER) said late Wednesday it has submitted a briefing package to the US Food and Drug Administration after the agency raised concerns about...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Omeros Corp. (OMER) said Thursday it has closed the sale of Omidria eye medication to Rayner Surgical in a deal valued in excess of $1 billion. The...
Health care stocks were ending off Thursday's pace, with the NYSE Health Care Index rising 0.5% this afternoon while the SPDR Health Care Select Sector ETF...
Health care stocks were trending higher this afternoon, with the NYSE Health Care Index rising 0.5% while the SPDR Health Care Select Sector ETF (XLV) was...
Biopharmaceutical firm Omeros (OMER) said Thursday it has agreed to sell the OMIDRIA franchise to Rayner Surgical Group in a deal valued at over $1...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Revance Therapeutics (RVNC) said late Friday that the Food and Drug Administration declined to approve its biologics license application for...